Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 3Lymphoma, Follicular 2Lymphoma, B-Cell 2Smoldering Multiple Myeloma 1Recurrence 1Meningeal Carcinomatosis 1Lymphoma 1Hodgkin Disease 1Disease Progression 1Burkitt Lymphoma 1

Interventions

Lenalidomide 8Dexamethasone 6Calcium Dobesilate 6Melphalan 3elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Peripheral Blood Stem Cell Transplantation 2Bortezomib 2pomalidomide 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1Watchful Waiting 1Urination 1Transplantation, Autologous 1Stem Cell Transplantation 1Receptors, Interleukin-6 1Observation 1Nivolumab 1Metformin 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1IPH-2101 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Smoldering Multiple Myeloma × Transplantation, Autologous × Clear all
NCT02353572 2015-03-09

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

University of Colorado, Denver

Phase 1/2 Terminated
3 enrolled 5 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡